Results 191 to 200 of about 43,976 (245)

IL4I1⁺ Macrophages and TDO2⁺ Myofibroblasts Drive AhR‐Mediated Immunosuppression and Ferroptosis Resistance in Solid Predominant Lung Adenocarcinoma

Advanced Science, Volume 13, Issue 13, 3 March 2026.
Solid predominant lung adenocarcinoma exhibits an immune‐excluded, ferroptosis‐resistant niche enriched with IL4I1⁺ TAMs and TDO2⁺ myCAFs. Spatial and multi‐omics analyses reveal AhR‐driven crosstalk that promotes T cell exhaustion and therapy resistance. Blocking AhR with CH‐223191 restores ferroptosis sensitivity, and its combination with ferroptosis
Zhaoxuan Wang, Weijiao Xu, Lei Zhao, Lin Zhong, Wendan Yu, Shengmin Wang, Lu Sun, Tao Guo, Fengzhou Li, Zhuoshi Li, Lei Fang, Shiqing Wang, Guohui Zhang, Guoqing Xue, Wei Guo, Shilei Zhao, Chundong Gu   +16 more
wiley   +1 more source

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy

American Journal of Hematology, Volume 101, Issue 3, Page 512-520, March 2026.
Early cardiac biomarker monitoring in AML induction therapy showed significantly higher hsTnT levels after daunorubicin 90 mg/m2 compared with 60 mg/m2, indicating a dose‐dependent early myocardial effect. ABSTRACT Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the ...
Stefan Markus Dendorfer, Katharina Schmidt‐Brücken, Michael Kramer, Björn Steffen, Christoph Schliemann, Jan‐Henrik Mikesch, Nael Alakel, Regina Herbst, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Barbora Weinbergerova, Kerstin Schäfer‐Eckart, Tim Sauer, Andreas Neubauer, Andreas Burchert, Claudia D. Baldus, Jolana Mertová, Edgar Jost, Dirk Niemann, Jan Novák, Stefan W. Krause, Sebastian Scholl, Andreas Hochhaus, Gerhard Held, Tomáš Szotkowski, Andreas Rank, Christoph Schmid, Lars Fransecky, Sabine Kayser, Markus Schaich, Frank Fiebig, Annett Haake, Johannes Schetelig, Jan Moritz Middeke, Friedrich Stölzel, Uwe Platzbecker, Christian Thiede, Carsten Müller‐Tidow, Wolfgang E. Berdel, Gerhard Ehninger, Jiri Mayer, Hubert Serve, Martin Bornhäuser, Christoph Röllig   +44 more
wiley   +1 more source

Perspectives on monitoring and diagnosis of chemotherapy-induced cardiotoxicity. [PDF]

World J Clin Cases
Méndez-Toro A.
europepmc   +1 more source

Cardiovascular Disease Mortality Patterns Among People With Cancer in New South Wales, Australia: A Population‐Wide Data Linkage Study

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Objective To investigate cardiovascular disease (CVD) mortality patterns among people with cancer in New South Wales (NSW) compared to the NSW general population and trends over time. Design Population‐wide retrospective data‐linkage study. Participants and Setting 873,344 people aged ≥ 40 diagnosed with primary invasive cancer and registered ...
Md Mijanur Rahman, Karen Canfell, Katy Bell, Grace Joshy, Michael David, Anne Cust, David Goldsbury, Bogda Koczwara, Emily Banks, Xue Qin Yu   +9 more
wiley   +1 more source

Refining the Role of Epigenetic Age Acceleration in Cardiotoxicity Research. [PDF]

JACC CardioOncol
Cao J, Han W, Liu Y.
europepmc   +1 more source

Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre‐Treated Human Epidermal Growth Factor Receptor 2‐Positive Metastatic Breast Cancer

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Purpose Findings from our previous study showed that the combination of pyrotinib, trastuzumab, and chemotherapy represents a viable treatment strategy with an acceptable safety profile for heavily pre‐treated human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer (MBC).
Xiaofeng Xie, Daijia Huang, Jiayi Huang, Xuelian Chen, Xue Bai, Wenyu Zheng, Liping Chen, Xiaofeng Lan, Lin Song, Rongmei Lei, Caiwen Du   +10 more
wiley   +1 more source

Caught in the crossfire: cardiac complications of cancer therapy. [PDF]

J Clin Invest
Guerra G, Mergiotti M, Ardehali H, Hirsch E, Ghigo A.   +4 more
europepmc   +1 more source

A Novel Modified Bu/Vp16/cy/Flu/Ara‐C Conditioning Regimen Enhances Outcomes for High‐Risk Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Purpose Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) effectively treats high‐risk acute lymphoblastic leukemia (ALL), yet challenges persist due to post‐transplant relapse and conditioning regimen toxicities. The determination of an appropriate preconditioning regimen is critical to improving patient outcomes.
Xiaoyan Zhao, Yifan Yao, Yan Sun, Ziwei Xu, Aiguo Liu, Xin Dong, Huafang Wang   +6 more
wiley   +1 more source

Low-Intensity Exercise Attenuates Immune Checkpoint Inhibitor-Induced Cardiotoxicity via Regulation of Metabolism and Autophagy. [PDF]

Cancers (Basel)
Tichy L, Parry TL.
europepmc   +1 more source

Pediatric Cardio-Oncology: From Gap in Evidence to Future Perspectives. [PDF]

Diagnostics (Basel)
Correra A, Cetoretta V, Maratea AC, Ferrara S, Di Sarno I, Russo V, Guerra F, Mauriello A, D'Andrea A.   +8 more
europepmc   +1 more source